Skip to main content
SpringerLink
Log in

No increased risk of cancer with telmisartan: UK results

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. ARBs = angiotensin receptor blockers

Reference

  • Tascilar K, et al. The Use of Telmisartan and the Incidence of Cancer. American Journal of Hypertension : [8 pages], 24 Aug 2016. Available from: URL: http://dx.doi.org/10.1093/ajh/hpw095

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

No increased risk of cancer with telmisartan: UK results. Reactions Weekly 1618, 10 (2016). https://doi.org/10.1007/s40278-016-21015-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-21015-4

Search

Navigation